Wegovy maker Novo shares slump as management grilled on pricing, M&A

Novo Nordisk shares slid as much as 9% on Monday as executives faced tough questions from analysts over the ‌drugmaker's pricing power and dealmaking strategy ahead of looming patent expiries.